CMND News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CM

Mkt Cap

$3.2M

Volume

3.28K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II TrialClearmind Medicine announced successful completion of treatment for all 24 participants in Part A of its Phase I/II clinical trial evaluating CMND-100 for alcohol use disorder. The multicenter trial, conducted under FDA oversight at leading U.S. and Israeli research institutions, is progressing to data review with plans to advance to the next phase of development pending favorable results.GlobeNewswire Inc. · Jul 28, 2026

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics MarketClearmind Medicine Inc. (Nasdaq: CMND) filed a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting PTSD treatment. The filing is part of an exclusive licensing agreement with Yissum Research Development Company of Hebrew University. The global PTSD treatment market is valued at USD 18.5 billion in 2025 and projected to reach USD 30.2 billion by 2035, with Clearmind positioning Hong Kong as a strategic gateway for Asian market access.GlobeNewswire Inc. · Jul 20, 2026

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price NotificationClearmind Medicine received a Nasdaq notice for not meeting minimum bid price requirements, with 180 days to regain compliance or risk potential delisting.GlobeNewswire Inc. · Dec 5, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsightThe substance use disorder market is expected to grow between 2025 and 2034, driven by greater awareness, the introduction of new therapies, and ongoing research and development efforts. The report covers the market assessment of Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder.GlobeNewswire Inc. · Apr 28, 2025

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersSciSparc and Clearmind Medicine have filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.GlobeNewswire Inc. · Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating DisordersClearmind Medicine has filed an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. The treatment combines 3-Methylmethcathinone (3-MMC) and Palmitoylethanolamide (PEA) to address the complex neurobiological and psychological factors associated with eating disorders.GlobeNewswire Inc. · Apr 25, 2025

Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeClearmind Medicine Inc. has been granted a patent by the Macau International Intellectual Property Office for its proprietary MEAI-based binge behavior regulator program. This patent further strengthens the company's global intellectual property portfolio, which now includes 31 granted patents across 18 patent families.GlobeNewswire Inc. · Jan 2, 2025

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol SubstituteClearmind Medicine Inc. has signed a non-binding term sheet with Dr Glitter Pty Ltd to collaborate on the development and commercialization of Clearmind's MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The partnership aims to provide a safe alternative to alcohol that can replicate the sensations of drinking without the associated health risks.GlobeNewswire Inc. · Dec 26, 2024

Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical TrialClearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder (AUD). The trial will be led at Yale School of Medicine's Department of Psychiatry, marking a significant step forward in Clearmind's FDA-regulated clinical program.GlobeNewswire Inc. · Dec 24, 2024

Alcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsightThe alcohol use disorder market is expected to show positive growth, with growing awareness about AUD and reduced stigma surrounding mental health issues encouraging more individuals to seek treatment during the forecast period (2024–2034).GlobeNewswire Inc. · Dec 11, 2024

CM

CMNDClearmind Medicine Inc. Common Shares

CMND

Pay with—

Available Balance0.00

Your PositionYou don't own any CMND yet.

Related Tickers

Earnings